Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.39 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2036751 | 1.00 | POLB (0.70) | POLBKDM4EALDH1A1GRM4HRH4 | |
| SCHEMBL2036753 | 1.00 | POLB (0.70) | POLBKDM4EALDH1A1GRM4HRH4 | |
| SCHEMBL2037576 | 0.85 | POLB (0.72) | POLBKDM4EALDH1A1MAP4K4ROCK1 | |
| SCHEMBL2037578 | 0.85 | POLB (0.72) | POLBKDM4EALDH1A1MAP4K4ROCK1 | |
| SCHEMBL2033986 | 0.84 | POLB (0.70) | POLBKDM4EALDH1A1HRH4ROCK1 | |
| SCHEMBL2035778 | 0.84 | POLB (0.70) | POLBKDM4EALDH1A1HRH4ROCK1 | |
| SCHEMBL2036606 | 0.84 | POLB (0.70) | POLBKDM4EALDH1A1MAP4K4ROCK1 | |
| SCHEMBL2033988 | 0.84 | POLB (0.70) | POLBKDM4EALDH1A1HRH4ROCK1 | |
| SCHEMBL2031730 | 0.83 | POLB (0.48) | POLBKDM4EALDH1A1GRM4HRH4 | |
| SCHEMBL2031729 | 0.83 | POLB (0.48) | POLBKDM4EALDH1A1GRM4HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516397-B1 | Amino-heteroaryl derivatives as HCN blockers | MERCK SHARP & DOHME (NL) | 2016-07-13 | — | — | EP | claimed |
| US-8952001-B2 | Amino-heteroaryl derivatives as HCN blockers | MERCK SHARP & DOHME CORP. (US) | 2015-02-10 | — | — | US | claimed |
| CN-102884048-B | Amino-heteroaryl derivatives as HCN blockers | MSD OSS BV | 2014-07-23 | — | — | CN | claimed |
| CN-102884048-A | Amino-heteroaryl derivatives as HCN blockers | MSD OSS BV | 2013-01-16 | — | — | CN | claimed |
| EP-2516397-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | MSD Oss B.V. (NL) | 2012-10-31 | — | — | EP | claimed |
| US-20120264728-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2012-10-18 | — | — | US | claimed |
| WO-2011076723-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | N.V. ORGANON (NL) | 2011-06-30 | — | — | WO | claimed |
| EP-2516397-B1 | Amino-heteroaryl derivatives as HCN blockers | MERCK SHARP & DOHME (NL) | 2016-07-13 | — | — | EP | disclosed |
| US-8952001-B2 | Amino-heteroaryl derivatives as HCN blockers | MERCK SHARP & DOHME CORP. (US) | 2015-02-10 | — | — | US | disclosed |
| CN-102884048-B | Amino-heteroaryl derivatives as HCN blockers | MSD OSS BV | 2014-07-23 | — | — | CN | disclosed |
| CN-102884048-A | Amino-heteroaryl derivatives as HCN blockers | MSD OSS BV | 2013-01-16 | — | — | CN | disclosed |
| EP-2516397-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | MSD Oss B.V. (NL) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264728-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2012-10-18 | — | — | US | disclosed |
| WO-2011076723-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | N.V. ORGANON (NL) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264728-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | HCN1, HCN3, HCN2 | POLB 3931/4885KDM4E 3696/4885ALDH1A1 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.